Functional MRI assessment of primary and secondary brain tumour response to radiation therapy: A pilot study
Not Applicable
Completed
- Conditions
- Brain CancerCancer - Brain
- Registration Number
- ACTRN12616000863437
- Lead Sponsor
- Dr Eng-Siew Koh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
18 years or older
Have the ability to give informed consent
Histologically-proven primary or secondary brain cancer
Plan to have radiotherapy treatment
Exclusion Criteria
Contraindication to MRI studies
Significant claustrophobia
Pacemaker/implantable defibrillator
Implanted metals eg. Intraocular clips
Known allergic reaction to Gd-DTPA
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine early treatment response and/or disease progression post cancer therapy using novel MRI sequences (including DW and DCE-MRI) in CNS cancer patients.[Baseline, Week 3, Week 6 and 4 Weeks post Radiotherapy<br><br>Baseline - DW, DCE, SWI and ASL MRI at radiotherapy simulation (week 0)<br>Weeks 3 and 6 - DW, DCE, SWI and ASL MRI <br>4 Weeks post RT - DW, DCE, SWI and ASL MRI<br>Abbreviations: DW = diffusion weighted; DCE = dynamic contrast enhanced; SWI = susceptibility weighted imaging; ASL = Arterial spin labelling]
- Secondary Outcome Measures
Name Time Method To document serial hippocampal volumetric changes post cancer therapy using novel MRI sequences.[Baseline, Week 3, Week 6 and 4 Weeks post Radiotherapy<br><br>Baseline - DW, DCE, SWI and ASL MRI at radiotherapy simulation (week 0)<br>Weeks 3 and 6 - DW, DCE, SWI and ASL MRI <br>4 Weeks post RT - DW, DCE, SWI and ASL MRI<br>Abbreviations: DW = diffusion weighted; DCE = dynamic contrast enhanced; SWI = susceptibility weighted imaging; ASL = Arterial spin labelling]